LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...

LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food ...

Please provide your email address to receive an email when new articles are posted on . The triple-combination gel was much more evenly applied than the layered ingredients in 100% of cases. 96% of ...

Two teens who previously used antibiotic topical acne gels experienced anaphylaxis following administration of IV clindamycin prior to third-molar surgeries, according to a case report published in ...

Please provide your email address to receive an email when new articles are posted on . IDP-126 — a combination of clindamycin, adapalene and benzoyl peroxide — reduced acne severity in about half of ...

Cabtreo combines clindamycin phosphate, a lincosamide antibacterial, adapalene, a retinoid, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic effects, into one topical gel.

LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health (BHC), Canada Inc., part of Bausch Health Companies Inc., today announced that Pr CABTREO TM (clindamycin phosphate, adapalene and benzoyl ...

The approval of Cabtreo was based on data from 2 placebo-controlled phase 3 studies. Cabtreo combines clindamycin phosphate, a lincosamide antibacterial, adapalene, a retinoid, and benzoyl peroxide, ...

Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel was shown to be safe and effective in Hispanic and Latino populations with moderate-to-severe acne. The post hoc analysis ...

LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that ...